Background: Aggressive statin treatment was found to slightly reduce testosterone production. The aim of this study was to compare the effects of ezetimibe-statin combination and high-dose statin therapy on testicular and adrenal cortex function in men with LDL cholesterol levels below 70 mg/dL.
Methods: The study included 26 adult men with coronary artery disease. Twelve of these patients did not tolerate high-dose statin therapy and were treated with lower doses of a statin plus ezetimibe. Fourteen patients tolerating high-dose simvastatin or rosuvastatin treatment continued high-dose statin therapy throughout the study period. Plasma lipids, glucose homeostasis markers and plasma levels of testosterone, cortisol, dehydroepiandrosterone sulphate, sex hormone-binding globulin, gonadotropins and ACTH, as well as urine free cortisol were assessed at baseline and after 16 weeks of treatment.
Results: Replacing high-dose statin therapy with ezetimibe/statin combination therapy reduced plasma levels of LH by 32% (p=0.043), as well as increased plasma levels of testosterone by 20% (p=0.038). Ezetimibe/statin combination did not induce any significant changes in plasma levels or urine excretion of the remaining hormones. At the end of the study, plasma LH levels were higher, while plasma testosterone levels were lower in patients receiving the combination therapy than in those treated only with high-dose statin.
Conclusions: Our results indicate that ezetimibe combined with moderate statin dose exerts a less pronounced effect on testicular function in comparison with high-dose statin therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pharep.2014.10.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: The effect of worsening renal function and baseline chronic kidney disease (CKD) on outcomes in patients with chronic coronary syndrome in the setting of optimal medical therapy remains unknown.
Methods And Results: The REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) study is a prospective, multicenter, randomized trial of high-dose (pitavastatin 4 mg/day) or low-dose (pitavastatin 1 mg/day) statin therapy in 12 118 patients with chronic coronary syndrome. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, or unstable angina requiring hospitalization (major adverse cardiac and cerebral events [MACCE]).
Cortical Hand Knob Stroke: A Case Report of Isolated Hand Weakness and Recovery.
Cureus
November 2024
Internal Medicine, Milton Keynes University Hospital, Milton Keynes, GBR.
Cortical hand knob stroke is a rare form of stroke that affects the motor cortex responsible for controlling fine hand movements. This condition, most commonly caused by ischemia in the "hand knob" region of the precentral gyrus, can present with isolated hand weakness, often mimicking peripheral neuropathies and leading to diagnostic delays. We report a case of a 65-year-old right-handed woman who experienced a sudden onset of left-hand weakness, along with resolving slurred speech and facial droop, while she was working at her office.
View Article and Find Full Text PDFNilotinib as an Independent Risk Factor for Stroke by Accelerated Atherosclerosis.
Cureus
November 2024
Neurology, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, IND.
Article Synopsis
- - Nilotinib, a medication for chronic myeloid leukemia, can lead to serious cardiovascular issues like atherosclerosis and arterial narrowing, especially in patients who use it long-term or at high doses.
- - A case study reported a stroke in a patient on nilotinib who had no prior stroke risk factors, highlighting potential risks of the drug despite the patient's initial safety.
- - After stopping nilotinib, the patient received treatments like antiplatelets and physiotherapy, which improved his condition, emphasizing the need for regular cardiovascular monitoring in patients on nilotinib.
Optimizing Outcomes in Heart Transplantation: The Role of High-Intensity Statin Therapy.
J Biochem Mol Toxicol
December 2024
Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey.
Heart transplantation is a vital procedure for patients with end-stage heart failure, but it faces significant challenges, including graft dysfunction, rejection, and cardiac allograft vasculopathy (CAV), which can compromise long-term graft success. Research suggests that statin therapy may offer significant benefits to heart transplant recipients, such as improved long-term survival and reduced rates of graft rejection and mortality. The aim of this review is to thoroughly examine the recent literature on this topic since 2005.
View Article and Find Full Text PDFThe clinical effectiveness and safety of low/moderate-intensity statins & ezetimibe combination therapy vs. high-intensity statin monotherapy: a systematic review and meta-analysis.
BMC Cardiovasc Disord
November 2024
Faculty of Medicine, Ain-Shams University, 56Th Abbaseyia Street, Cairo, Egypt.
Background: Despite widespread use of high-intensity statin monotherapy, achieving target LDL-C levels and reducing cardiovascular events in patients with or at high risk of developing ASCVD remains challenging. Our study measured the effects of low/moderate-intensity statins and ezetimibe combination therapy compared to high-dose statin monotherapy on major adverse cardiovascular events (MACEs) and coronary atherosclerotic plaque reduction.
Methods: We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL register of trials for studies comparing the combination therapy to high-intensity statin monotherapy in terms of MACEs and coronary atherosclerotic plaque reduction.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!